leadf
logo-loader
TSX:ATE OTCQB:ATBPF

Antibe Therapeutics Inc

Receive alerts
Market:
TSX
Market Cap:
$211.15 m
Price
4.64 CAD
Change
-6.64%
52 weeks high
8.90
52 weeks low
3.05

In brief

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation, safer nonsteroidal anti-inflammatory drugs (“NSAIDs”) for pain and inflammation arising from a wide range of medical conditions. Antibe is developing three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with NSAIDs. Antibe’s lead drug, otenaproxesul (ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. 

 

Snapshot

The company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic use

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Antibe’s breakthrough osteoarthritis pain relief drug in the spotlight on World Arthritis Day

The company’s lead drug otenaproxesul, formerly known as ATB-346, could be a home run if it performs in Phase 3 clinical trials in the US

on 10/12/2020